A nurse reviews the medication prescriptions for a client with chronic kidney disease (CKD). Which of the following prescriptions should the nurse ask about due to the potential to worsen the client's renal function?

Choice A rationale This water soluble vitamin is essential for red blood cell production and DNA synthesis. In chronic kidney disease, patients often lose this nutrient during dialysis or have decreased intake due to dietary restrictions. Supplementation is standard practice and does not harm renal tissue. It supports erythropoiesis alongside other treatments for anemia of chronic disease. Normal serum levels typically range from 5 to 25 ng/mL depending on the laboratory reference. Choice B rationale Angiotensin converting enzyme inhibitors like this one are often used in kidney disease to provide renoprotection. By dilating the efferent arteriole, they reduce intraglomerular pressure and slow the progression of albuminuria. While they can cause a transient rise in creatinine or potassium, they are generally beneficial rather than harmful. Close monitoring of serum potassium, normally 3.5 to 5.0 mEq/L, and creatinine, normally 0.6 to 1.2 mg/dL, is required during therapy. Choice C rationale Nonsteroidal anti-inflammatory drugs inhibit prostaglandin synthesis by blocking cyclooxygenase enzymes. Prostaglandins are critical for maintaining renal vasodilation and adequate blood flow in patients with compromised kidney function. Blocking these compounds causes afferent arteriolar constriction, reducing the glomerular filtration rate and potentially inducing acute kidney injury. These medications should be avoided in renal impairment because they directly worsen ischemia and can accelerate the progression to end stage renal disease. Choice D rationale This medication is a synthetic form of a hormone normally produced by the kidneys to stimulate bone marrow production of red blood cells. Patients with renal failure often develop anemia because of erythropoietin deficiency. Administering this agent helps maintain hemoglobin levels within the target range, usually 10 to 12 g/dL for these patients. It is a vital supportive therapy that addresses a common complication of the disease without causing direct nephrotoxicity.